Semin Thromb Hemost 2003; 29(6): 585-594
DOI: 10.1055/s-2004-815626
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Advances in Care of Children with Hemophilia

Marilyn J. Manco-Johnson1,2 , Brenda  Riske2 , Carol K. Kasper3
  • 1Professor of Pediatrics, Mountain States Regional Hemophilia and Thrombosis Center, University of Colorado Health Sciences Center and The Children's Hospital, Denver, Colorado
  • 2Director, Mountain States Regional Hemophilia and Thrombosis Center, University of Colorado Health Sciences Center and The Children's Hospital, Denver, Colorado
  • 3Orthopedic Hospital, Los Angeles, California
Further Information

Publication History

Publication Date:
13 January 2004 (online)

ABSTRACT

Care for children with severe hemophilia has moved from pediatric hospital wards and rehabilitation services to the home, school, and community. Advances in hemophilia are due largely to the development of specialized hemophilia treatment centers, which created a system of comprehensive care and focused healthcare efforts on prevention and education. Parallel advances in coagulation resulted in identification of clotting factors VIII and IX, elucidation of the protein molecular and biochemical structures and functions, sequencing of their respective genes and transfer of the human genes for production of proteins by recombinant technology, and development of gene therapy. The tragedy of the human immunodeficiency virus and hepatitis C raised awareness in patients as well as healthcare providers of the vulnerability of blood products to viral contamination and spurred progress in science leading to viral inactivation of purified proteins. Concomitantly, physicians treating bleeding episodes in the clinic investigated pharmacokinetics and pharmacoeconomics of various strategies of clotting factor replacement. The observation that trough factor levels as low as 1 to 2% were adequate to prevent most bleeding episodes led to current prophylactic regimens that allow boys to participate fully in school and community activities while factor concentrate is infused at home on a regular schedule. Currently, children with hemophilia look forward to a normal life expectancy and excellent health-related quality of life. Physician and community partnerships through research and advocacy societies have accelerated clinical advancements as well as extension of treatment to developing countries. The future of hemophilia promises a cure with gene therapy. Given the past accomplishments in hemophilia, a long-term solution to replacement of the genetically deficient protein lies on the horizon.

REFERENCES

  • 1 Biggs R. Thirty years of haemophilia treatment in Oxford.  Br J Haematol . 1967;  13 452-463
  • 2 Birch C LaF. Hemophilia, Clinical and Genetic Aspects.  Urbana, IL: University of Illinois; 1937
  • 3 Macfarlane R G, Barnett B. The haemostatic possibilities of snake-venom.  Lancet . 1934;  ii 985-987
  • 4 Marfarlane R G. The normal haemostatic mechanism and its failure in the haemorrhagic states.  Thesis for the degree of M.D. London: University of London; 1938
  • 5 Biggs R, Douglas A S, Macfarlane R G. The formation of thromboplastin in human blood.  J Physiol (Lond) . 1953;  119 89-101
  • 6 Biggs R, Douglas A S, Macfarlane R G. The initial stages of blood coagulation.  J Physiol (Lond) . 1953;  122 538-553
  • 7 Rapaport S I, Schiffman S, Patch M J. et al . A simple, specific one-stage assay for plasma thromboplastin antecedent activity.  J Lab Clin Med . 1961;  57 771-780
  • 8 Thompson A R. Structure and function of the factor VIII gene and protein.  Semin Thromb Hemost . 2003;  29 11-22
  • 9 Kurachi K, Kurachi S, Furukawa M, Yao S N. Biology of factor IX.  Blood Coagul Fibrinolysis . 1993;  4 953-973
  • 10 Gitschier J, Wood W I, Goralka T M. et al . Characterization of the human factor VIII gene.  Nature . 1984;  312 326-330
  • 11 Anson D S, Choo K H, Rees D J. et al . The gene structure of human anti-haemophilic factor IX.  EMBO J . 1984;  3 1053-1060
  • 12 Saenko E L, Shima M, Sarafanov A G. Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex.  Trends Cardiovasc Med . 1999;  9 185-192
  • 13 Butenas S, van `t Veer C, Cawthern K, Brummel K E, Mann K G. Models of blood coagulation.  Blood Coagul Fibrinolysis . 2000;  11 (suppl 1S) 9-13
  • 14 Biggs R, Macfarlane R G. Haemophilia and related conditions: a survey of 187 cases.  Br J Haematol . 1958;  4 1-27
  • 15 Biggs R, Macfarlane R G. Treatment of Haemophilia and Other Coagulation Disorders.  Oxford, UK: Blackwell Scientific; 1966
  • 16 Kasper C K. A total program for the patient with hemophilia.  J Am Phys Ther Assoc . 1966;  46 1268-1285
  • 17 Praga C, Cortellaro M. Organizational aspects of comprehensive assistance to hemophiliacs.  Haematol Lat . 1969;  12 667-673
  • 18 Kerr C B. Comprehensive care for haemophilia.  J R Coll Physicians Lond . 1971;  5 263-267
  • 19 Allain J P. A boarding school for hemophiliacs: a model for the comprehensive care of hemophilic children.  Ann N Y Acad Sci . 1975;  240 226-237
  • 20 Levine P H, McVerry B A, Segelman A E, Cranford C M, Zimbler S. Comprehensive health care clinic for hemophiliacs.  Arch Intern Med . 1976;  136 792-794
  • 21 Tann G. Recent advances in hemophilia.  Southeast Asian J Trop Med Public Health . 1979;  10 218-228
  • 22 PL 9463: The Public Health Service Act establishing the hemophilia diagnostic and treatment center program. No. 1131 of Public Law 9463.  Washington, DC: Government Printing Office; 1975
  • 23 Fearns M. The management of clinical specialties: the nurse's role in the management of a haemophilia centre.  Nurs Focus . 1982;  3 8-9
  • 24 Smith P S, Keyes N C, Forman E N. Socioeconomic evaluation of a state-funded comprehensive hemophilia-care program.  N Engl J Med . 1982;  306 575-579
  • 25 Smith P S, Levine P H. The benefits of comprehensive care of hemophilia: a five-year study of outcomes.  Am J Public Health . 1984;  74 616-617
  • 26 Levine P H, Brackmann H H, Seligsohn U. A proposed system of classification of hemophilia centers for the World Federation of Hemophilia (WFH).  Scand J Haematol . 1984;  40(suppl) 459-460
  • 27 Soucie J M, Nuss R, Evatt B, et a l, and the Hemophilia Surveillance System Project Investigators. Mortality among men with hemophilia: relations with source of medical c are. Blood .  2000;  96 437-442
  • 28 Rabiner S F, Telfer M C. Home transfusion for patients with hemophilia A.  N Engl J Med . 1970;  283 1011-1015
  • 29 Levine P H. Efficacy of self-therapy in hemophilia. A study of 72 patients with hemophilia A and B.  N Engl J Med . 1974;  291 1381-1384
  • 30 Jones P, Fearns M, Forbes C, Stuart J. Haemophilia A home therapy in the United Kingdom 1975-6.  BMJ . 1978;  1 1447-1450
  • 31 Evensen S A, Thaule R, Grøan K. Self-therapy for haemophilia in Norway.  Acta Med Scand . 1979;  205 395-399
  • 32 Allain J P, Blombäck M, Brackmann H H. et al . Recommendations on home treatment of hemophilias.  Scand J Haematol . 1977;  31(suppl) 75-77
  • 33 Soucie J M, Symons IV J, Evatt B, Brettler D, Huszti H, Linden J. The Hemophilia Surveillance System Project Investigators. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia.  Haemophilia . 2001;  7 198-206
  • 34 Miller K, Buchanan G R, Zappa S. et al . Implantable venous access devices in children with hemophilia: a report of low infection rates.  J Pediatr . 1998;  132 934-938
  • 35 Ljung R, van den Berg M, Petrini P. et al . Port-a-cath usage in children with haemophilia: experience of 53 cases.  Acta Paediatr . 1998;  87 1051-1054
  • 36 Geraghty S, Kleinert D. Use and morbidity of venous access devices in patients with hemophilia.  J Intraven Nurs . 1998;  21 70-75
  • 37 Perkins J L, Johnson V A, Osip J M. et al . The use of implantable venous access devices (IVADs) in children with hemophilia.  J Pediatr Hematol Oncol . 1997;  19 339-344
  • 38 Van Den Berg M H, Fischer K, Roosendaal G, Mauser-Bunschoten E P. The use of the port-a-cath in children with haemophilia-a review.  Haemophilia . 1998;  4 418-420
  • 39 Medeiros D, Miller K L, Rollins N K, Buchanan G R. Contrast venography in young haemophiliacs with implantable central venous access devices.  Haemophilia . 1998;  4 10-15
  • 40 Hoots W K. History of plasma-product safety.  Transfus Med Rev . 2001;  15(2 suppl 1) 3-10
  • 41 Mannucci P M, Colombo M. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates.  Thromb Haemost . 1989;  61 532-534
  • 42 Pool J G, Shannon A E. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.  N Engl J Med . 1965;  273 1443-1447
  • 43 Hershgold E J, Pool J G, Pappenhagen A R. The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: characterization and further data on preparation and clinical trial.  J Lab Clin Med . 1966;  67 23-32
  • 44 Tullis J L, Melin M, Jurigian P. Clinical use of human prothrombin complexes.  N Engl J Med . 1965;  273 667-674
  • 45 Kasper C K, Kipnis S A. Hepatitis and clotting factor concentrates (letter).  JAMA . 1972;  221 510
  • 46 Biggs R, Rizza C RC, Blackburn E K. et al . Factor VIII concentrates made in the United Kingdom and the treatment of haemophilia based on studies made 1969-72. Report of the medical research council's blood transfusion research committee working party on the cryoprecipitate method of preparing AHF concentrates.  Br J Haematol . 1974;  27 391-405
  • 47 Seeff L B, Hoofnagle J. Acute and Chronic Liver Disease in Hemophilia. Unsolved therapeutic problems in hemophilia. Proceedings of a conference sponsored by the Bureau of Biologics, FDA, Division of Blood Diseases and Resources, NHLBI, National Hemophilia Foundation. Bethesda, MD, March 1976. Fratantoni JC, Aronson DL, eds. DHEW Publication no (NIH) 77-1089. Washington, DC: U.S. Department of Health Education and Welfare, Public Health Service, NIH 1976: 61-72
  • 48 Triger D R, Preston F E. Chronic liver disease in haemophiliacs.  Br J Haematol . 1990;  74 241-245
  • 49 Gerety R J, Aronson D L. Plasma derivatives and viral hepatitis.  Transfusion . 1982;  22 347-351
  • 50 Brettler D B, Forsberg A D, Levine P H, Petillo J, Lamon K, Sullivan J L. Factor VIII: C concentrate purified from plasma using monoclonal antibodies: human studies.  Blood . 1989;  73 1859-1863
  • 51 Robertson B H, Alter M J, Bell B P. et al . Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission.  Biologicals . 1998;  26 95-99
  • 52 Blumel J, Schmidt I, Effenberger W. et al . Parvovirus B19 transmission by heat-treated clotting factor concentrates.  Transfusion . 2002;  42 1473-1481
  • 53 Teitel J M. Viral safety of haemophilia treatment products.  Ann Med . 2000;  32 485-492
  • 54 Tabor E, Epstein J S. NAT screening of blood and plasma donations; evolution of technology and regulatory policy.  Transfusion . 2002;  42 1230-1237
  • 55 Biggerstaff B J, Peterssen L R. Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City.  Transfusion . 2002;  42 1019-1026
  • 56 Evatt B. Creutzfeldt-Jakob disease and haemophilia: assessment of risk.  Haemophilia . 2000;  6 (suppl 1) 94-99
  • 57 Lusher J M. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy and inhibitor development.  Semin Thromb Hemost . 2002;  28 273-276
  • 58 Brinkhouse K, Sandberg H, Widlund L. et al . Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII.  Semin Thromb Hemost . 2002;  28 269-272
  • 59 Lusher J M, Lee C A, Kessler C M, Bedrosian C L. The ReFacto Phase 3 Study Group.  Haemophilia . 2003;  9 38-49
  • 60 Mikaelsson M, Oswaldsson U, Jankowski M. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII.  Semin Hematol . 2001;  38 13-23
  • 61 White II C G, Beebe A, Nielsen B. Recombinant factor IX.  Thromb Haemost . 1997;  78 261-265
  • 62 Evatt B L. Prions and haemophilia: assessment of risk.  Haemophilia . 1998;  4 628-633
  • 63 Reid W O, Lucas O N, Francisco J, Geisler P H, Erslev A J. The use of epsilon-aminocaproic acid in the management of dental extractions in the hemophiliac.  Am J Med Sci . 1964;  248 184-188
  • 64 Bennett A E, Ingram G I, Inglish P J. Antifibrinolytic treatment in haemophilia: a controlled trial of prophylaxis with tranexamic acid.  Br J Haematol . 1973;  24 83-88
  • 65 Mannucci P M, Ruggeri Z M, Pareti F I, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases.  Lancet . 1977;  1 869-872
  • 66 Smith T J, Gill J C, Ambruso D R, Hathaway W E. Hyponatremia and seizures in young children given DDAVP.  Am J Hematol . 1989;  31 199-202
  • 67 Ingerslev J, Feldstedt M, Sindet-Pedersen D. Control of haemostasis with recombinant factor VIIa in patient with inhibitor to factor VIII.  Lancet . 1991;  338 831-832
  • 68 Hoffman M, Monroe III M D. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.  Semin Hematol . 2001;  38 (suppl 12) 6-9
  • 69 Shapiro A. Inhibitor treatment: state of the art.  Dis Mon . 2003;  49 22-38
  • 70 Rakocz M, Mazar A, Varon D, Spierer S, Blinder D, Martinowitz U. Dental extractions in patients with bleeding disorders. The use of fibrin glue.  Oral Surg Oral Med Oral Pathol . 1993;  75 280-282
  • 71 Johnson J B. The management of hemophilia with lyophile human plasma intravenously injected.  JAMA . 1942;  118 799-802
  • 72 Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B.  Acta Orthop Scand . 1965;  77(suppl) 3-132
  • 73 Robinson P M, Tittley P, Smiley R K. Prophylactic therapy in classical hemophilia: a preliminary report.  Can Med Assoc J . 1967;  97 559-561
  • 74 Shanbrom E, Thelin G M. Experimental prophylaxis of severe hemophilia with a factor VIII concentrate.  JAMA . 1969;  208 1853-1856
  • 75 Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia.  Acta Haematol . 1969;  41 206-214
  • 76 Hirschman R J, Itscoitz S B, Shulman N R. Prophylactic treatment of factor VIII deficiency.  Blood . 1970;  35 189-194
  • 77 Kasper C K, Dietrich S L, Rapaport S I. Hemophilia prophylaxis with factor VIII concentrate.  Arch Intern Med . 1970;  125 1004-1009
  • 78 Aronstam A, Arblaster P G, Rainsford S G. et al . Prophylaxis in haemophilia: a double-blind controlled trial.  Br J Haematol . 1976;  33 81-90
  • 79 Aronstam A, Kirk P J, McHardy J W. et al . Twice weekly prophylactic therapy in haemophilia A.  J Clin Pathol . 1977;  30 65-67
  • 80 Nilsson I M, Blombäck M, Ahlberg Ä. Our experience in Sweden with prophylaxis on haemophilia. The hemophiliac and his world.  Bibl Haematol . 1970;  34 111-124
  • 81 Nilsson I M, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.  J Intern Med . 1992;  232 25-32
  • 82 Manco-Johnson M J, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia.  Am J Hematol . 1994;  47 113-117
  • 83 Hacker M R, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia.  Haemophilia . 2001;  7 392-396
  • 84 Manco-Johnson M J, Blanchette V. North American prophylaxis studies for persons with severe hemophilia: background, rationale and design.  Haemophilia . 2003;  9 (suppl 1) 44-49
  • 85 DiMichele D M. Inhibitors in haemophilia: a primer.  Haemophilia . 2000;  6 (suppl 1) 38-40
  • 86 Lollar P, Healey J F, Barrow R T, Parker E T. Factor VIII inhibitors.  Adv Exp Med Biol . 2001;  489 65-73
  • 87 Scandella D H. Properties of anti-factor VIII inihibitor antibodies in hemophilia patients.  Semin Thromb Hemost . 2000;  26 137-142
  • 88 Kasper C K, Aledort L M, Aronson D. et al . Proceedings: a more uniform measurement of factor VIII inhibitors.  Thromb Diath Haemorrhag (Stuttg) . 1975;  34 619-872
  • 89 Fakharzadeh S S, Kazazian Jr H H. Correlation between factor VIII genotype and inhibitor development in hemophilia A.  Semin Thromb Hemost . 2000;  26 167-171
  • 90 Oldenburg J, Brackmann H H, Schwaab R. Risk factors for inhibitor development in hemophilia A.  Haematologica . 2000;  85(10 suppl) 7-13
  • 91 Goodeve A C, Peake I R. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development.  Semin Thromb Hemost . 2003;  29 23-30
  • 92 Gill J. The role of genetics in inhibitor formation.  Thromb Haemost . 1999;  82 500-504
  • 93 Fijnvandraat K, Bril W S, Voorberg J. Immunobiology of inhibitor development in hemophilia A.  Semin Thromb Hemost . 2003;  29 61-68
  • 94 Aledort L M, Miners A, Bohn R. et al . Economic aspects of haemophilia care.  Haemophilia . 1999;  5 216-219
  • 95 Nilsson I M, Hedner U, Bjorlin G. Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide.  Ann Intern Med . 1973;  78 91-95
  • 96 Nilsson I M, Hedner U, Holmberg L. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide.  Acta Med Scand . 1974;  1-2 64-72
  • 97 Nilsson I M, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.  N Engl J Med . 1988;  318 947-950
  • 98 Brackmann H H, Gormsen J. Massive factor VIII infusion in hemophiliacs with factor VIII inhibitor, high responder.  Lancet . 1977;  2 933
  • 99 Mauser-Bunschoten E P, Nieuwerhuis H K, Rosendaal G, van den Berg M H. Low dose immune tolerance induction in hemophilia A patients with inhibitors.  Blood . 1995;  86 983-988
  • 100 DiMichele D, Kroner B. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.  Thromb Haemost . 2002;  87 52-57
  • 101 Hay C RM. Immune tolerance induction: prospective clinical trials.  Haematologica . 2000;  85 52-56
  • 102 Hilgartner M W. Current treatment of hemophilic arthropathy.  Curr Opin Pediatr . 2002;  14 46-49
  • 103 Fischer M, Modder G. Radionuclide therapy of inflammatory joint diseases.  Nucl Med Commun . 2002;  23 829-831
  • 104 Manco-Johnson M J, Nuss R, Lear J. et al . 32P Radiosynoviorthesis in children with hemophilia.  J Pediatr Hematol Oncol . 2002;  24 534-539
  • 105 Siegel H J, Luck J V, Siegel M E, Quinones C. Phosphate-32 colloid radiosynovectomy in hemophilia: outcome of 125 procedures.  Clin Orthop . 2001;  392 409-417
  • 106 Gilbert M S, Radomisli T E. Therapeutic options in the management of hemophilic synovitis.  Clin Orthop . 1997;  343 88-92
  • 107 Wiedel J D. Arthroscopic synovectomy of the knee in hemophilia: 10-to-15 year followup.  Clin Orthop . 1996;  328 46-53
  • 108 Carman C J. Developing and maintaining of hemophilia programs in developing countries.  Southeast Asian J Trop Med Public Health . 1993;  24 (suppl 1) 46
  • 109 Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world.  Haemophilia . 1998;  4 474-480
  • 110 Evatt B L, Robillard L. Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism.  Haemophilia . 2000;  6 131-134
  • 111 Isarangkura P. Haemophilia care in the developing world: benchmarking for excellence.  Haemophilia . 2002;  8 205-210
  • 112 High K A. Gene transfer as an approach to treating hemophilia.  Semin Thromb Hemost . 2003;  29 107-119